Medicis and Anacor to Develop Boron Treatments for Acne

Written by on April 8, 2011 in Acne Treatments, New Rosacea Treatments with 1 Comment


Even though this press release relates to Acne, it is still interesting to see companies searching for the next killer acne treatment. Whilst only some acne treatments are successful as rosacea treatments, we can still hope that this sort of research may lead to new treatments that are gentle and effective for rosacea sufferers as well. Certainly there is need for a treatment for severe acne to replace the maligned accutane.

Medicis is known to rosacea sufferers for making the medicated cleanser Plexion and the slow release minocycline Solodyn. Recently Medicis have announced that they are also trialing Ziana Gel (clindamycin phosphate 1.2% and tretinoin 0.025%) as a rosacea treatment.

Anacor and Medicis Enter Into Research and Development Collaboration for the Treatment of Acne

February 10, 2011

PALO ALTO, Calif. & SCOTTSDALE, Ariz.–(BUSINESS WIRE)– Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) and Medicis Pharmaceutical Corporation (NYSE:MRX) today announced that the two companies have entered into a research and development agreement to discover and develop boron-based small molecule compounds directed against a target for the potential treatment of acne.

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds which are currently in development, including its three lead programs:

  • AN2690, a topical antifungal for the treatment of onychomycosis;
  • AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and
  • GSK 2251052, or GSK ‘052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies’ research and development agreement.

In addition, Anacor is developing

  • AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and
  • AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.

For some background see; A Novel Borinic Acid Ester with Antibacterial Activity Against Propionibacterium acnes, an AAD Poster Session handout from 2006 referring to AN0128;

AN0128 (3-hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)-borane) is a novel compound that contains a boron atom within a borinic acid complex. AN0128 has broad spectrum activity against a wide variety of Gram positive bacteria, including many that are known skin colonizers.  Of particular and its causal role in acne vulgaris. 

The rise in antibiotic  P. acnes importance is to standard antibiotics necessitates the development of new P. acnes resistance of treatment agents.

AN0128 is a good candidate for a topical antibiotic and is currently being developed by Anacor as a novel therapeutic for acne and atopic dermatitis.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

1 Reader Comment

  1. sk says:

    I’ve been taking both lugol’s iodine solution and ionic boron, not sure which it is or a combo, but definitely since taking boron I’ve been amazed that I don’t get zits or blackheads on my face or back like I usually do when uni’s busy and I miss a few showers!

    Dosage I take about 5mg (2 drops) ionic boron and 3 drops lugol’s 7%… still slowly increasing my lugol’s dose over time to get used to taste/ effects. I have no idea what a good dose of boron is though. So annoying that there’s such scant info on boron. Overall though I’d say it’s changed me significantly, mentally and physiologically, so much more energy and mental concentration and less blackheads and stuff as I said.

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.